GlassScriptPhysician profile
Mariana Petrozzi
NPI 1346260973
$2,979.63
in general payments reported to CMS, 2019-2025
20 companies · $1,664 in 2025
The $1,664 reported for 2025 was more than what 84% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74.86 · 2020: $53.89 · 2024: $1,186 · 2025: $1,664.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,656 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,656.26 |
| Education | $194.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $613.47 | 2024-2025 | Fasenra, Breztri, Tezspire |
| Regeneron Healthcare Solutions, INC. | $418.30 | 2024-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $355.98 | 2019-2025 | Ofev, Jascayd |
| Glaxosmithkline, LLC. | $280.05 | 2020-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $250.30 | 2024-2025 | Glassia |
| Genzyme Corporation | $168.93 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $149.69 | 2025 | Acthar |
| Grifols USA, LLC | $149.01 | 2024-2025 | Prolastin-C Liquid |
| Actelion Pharmaceuticals US, INC. | $116.53 | 2024 | Uptravi, Opsumit |
| United Therapeutics Corporation | $89.30 | 2024-2025 | Tyvaso, Tyvaso |
| Amgen INC. | $71.62 | 2024-2025 | Tezspire |
| Insmed, INC. | $70.47 | 2024-2025 | Arikayce, Brinsupri |
| Viatris Specialty LLC | $64.03 | 2025 | Yupelri |
| Inogen, INC. | $53.60 | 2024 | |
| Verona Pharma, INC. | $36.78 | 2025 | Ohtuvayre |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $22.02 | 2025 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Mylan Specialty L.P. | $19.90 | 2020 | |
| Electromed, INC. | $17.66 | 2025 | Smartvest |
| Janssen Pharmaceuticals, INC | $16.56 | 2024 | Xarelto |
| Circassia INC. | $15.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mariana Petrozzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.